typei
interferon
ifn
cytokin
nonspecif
antivir
activ
particip
mostli
innat
defens
mechan
administr
propos
treat
sever
viral
immunomedi
diseas
immunomodulatori
therapi
due
avail
recombin
human
interferonalpha
studi
relat
felin
retrovirosi
vitro
vivo
howev
ifn
speciesspecif
antibodi
shown
develop
respons
high
dose
necessari
effect
therapi
recombin
felin
ifn
develop
character
interferonomega
rfeifn
design
overcom
problem
nonetheless
studi
undertaken
evalu
efficaci
cat
natur
infect
fiv
felv
initi
studi
demonstr
rfeifncan
dramat
improv
clinic
condit
infect
cat
induc
improv
hematolog
paramet
minor
chang
chang
observ
hypergammaglobulinemia
ratio
provir
load
viremia
rt
activ
suggest
overal
effect
ifn
innat
immun
studi
need
order
better
understand
vivo
mechan
felin
retrovirus
notabl
felin
leukemia
viru
felv
felin
immunodefici
viru
fiv
induc
chronic
infect
eventu
lead
progress
weaken
cat
presenc
variou
clinic
sign
advanc
stage
diseas
immun
suppress
establish
may
contribut
death
anim
review
hartmann
sellon
hartmann
treatment
anim
retrovir
diseas
usual
base
support
symptomat
therapi
rehydr
need
control
secondari
infect
antibiot
antiparasit
antifung
drug
among
other
administr
antivir
drug
uncommon
hartmann
sellon
hartmann
dunham
graham
antivir
use
felin
retrovirosi
use
human
medicin
includ
azt
zidovudin
ribavirin
zalcitabin
foscarnet
singularli
combin
use
drug
cat
sever
disadvantag
dose
protocol
well
establish
toxic
anim
well
produc
secondari
effect
caney
hartmann
sellon
hartmann
dunham
graham
infect
accompani
wide
array
clinic
sign
anemia
gingiv
anorexia
secondari
respiratori
infect
tumor
etc
prefer
cur
treatment
thu
reason
see
front
matter
elsevi
bv
right
reserv
altern
treatment
use
immunomodul
particularli
typei
interferon
addit
antivir
effect
aim
present
work
review
literatur
possibl
use
interferonomega
ifn
treat
felin
retrovirosi
describ
result
preliminari
studi
conduct
cat
infect
either
felv
fiv
observ
clinic
biopatholog
virolog
effect
innat
immun
play
role
protect
retrovir
infect
lehner
et
al
includ
intracellular
innat
antivir
factor
extracellular
factor
particularli
interferon
interferon
ifn
cytokin
import
multipl
biolog
function
interferon
classifi
typei
typeii
ifn
pestka
et
al
typei
ifn
produc
virusinfect
cell
nonspecif
antivir
activ
adjac
noninfect
cell
thu
known
viral
ifn
associ
innat
immun
interferon
includ
ifn
among
other
gener
mechan
action
base
interact
specif
cell
surfac
receptor
subsequ
induct
express
interferonstimul
gene
sen
pestka
et
al
cytokin
also
induc
antiprolif
antiinflammatori
respons
therefor
also
particip
adapt
immun
respons
gerlach
et
al
gerlach
et
al
thu
administr
typei
ifn
propos
treatment
sever
viral
diseas
immunomodulatori
therapi
truyen
et
al
collado
et
al
product
use
empir
quit
success
felin
medicin
without
profound
knowledg
molecular
mechan
efficaci
human
felin
clinic
first
evalu
first
one
commerci
avail
recombin
roferon
well
one
highest
vitro
antivir
effect
even
though
clinic
improv
lengthen
life
expect
infect
cat
observ
sever
disadvantag
soon
becam
appar
activ
vivo
may
lower
expect
cytokin
activ
often
speciesrestrict
would
less
effect
felin
cell
human
cell
inject
higher
dose
ukgday
abl
induc
adequ
serum
level
may
lead
develop
specif
neutral
antibodi
block
activ
ingredi
may
advers
effect
caney
disadvantag
could
overcom
administr
speciesspecif
felin
ifn
feifn
sever
subtyp
recombin
describ
could
potenti
benefit
treat
chronic
viral
infect
cat
given
vitro
antivir
activ
wonderl
et
al
howev
date
avail
clinic
use
although
recombin
felin
interferon
omega
rfeifn
commerci
avail
use
rel
success
felin
viral
infect
variou
etiolog
ifn
typei
ifn
secret
viru
infect
leukocyt
identifi
hauptmann
swetli
one
recent
character
interferon
adolf
initi
describ
human
encod
multipl
ifnor
ifn
like
gene
present
across
mammalian
group
includ
cat
robert
et
al
like
typei
ifn
ifnha
speciesrestrict
biolog
activ
vitro
abl
bind
typei
ifn
receptor
complex
typei
ifn
therefor
exert
similar
antivir
antiprolif
immunomodulatori
effect
adolf
howev
antigen
structur
distantli
relat
crossreact
antibodi
adolf
rfeifnthat
develop
nakamura
et
al
ueda
et
al
homolog
human
amino
acid
sequenc
consist
amino
acid
residu
nglycosyl
site
amino
acid
posit
recombin
ifn
character
omega
basi
amino
acid
ident
process
pattern
ntermin
sequenc
ueda
et
al
adolf
proven
antivir
effect
vitro
mochizuki
et
al
truyen
et
al
ohe
et
al
vivo
canin
felin
parvoviru
herpesviru
caliciviru
coronaviru
rotaviru
truyen
et
al
de
mari
et
al
ishida
et
al
paltrinieri
et
al
addit
pharmacokinet
properti
rfeifnar
compar
human
interferon
residu
accumul
bodi
ueda
et
al
licens
use
veterinari
medicin
virbagen
virbac
europ
japan
australia
new
zealand
mexico
although
clinic
studi
support
use
vivo
molecular
mechan
well
understood
gener
improv
clinic
sign
describ
justifi
use
infect
treatment
fulli
effect
retrovir
diseas
vitro
effect
ifni
human
retrovirus
extens
studi
gener
result
studi
shown
retrovir
protein
synthesi
affect
suggest
ifn
affect
latter
stage
viral
cycl
prevent
correct
assembl
releas
viral
particl
review
et
al
unfortun
studi
focus
effect
cytokin
felin
retrovirus
roger
et
al
jameson
essex
yamamoto
et
al
tanab
yamamoto
collado
et
al
review
literatur
collado
et
al
compar
effect
roferon
rfeifn
virbagen
persist
felvinfect
felin
cell
result
indic
retrovirus
rfeifnaffect
felv
cycl
posttranscript
level
protein
synthesi
alter
rt
activ
use
estim
number
infecti
particl
decreas
dosedepend
manner
given
ic
rfeifnappear
around
time
potent
inhibit
rt
addit
studi
reveal
ifn
induc
decreas
viabil
felvinfect
cell
enhanc
apoptosi
infect
cell
treat
signific
effect
cell
viabil
vivo
impact
present
unknown
case
fiv
similar
experi
rfeifnin
infect
felin
cell
shown
compar
result
felv
tanab
yamamoto
collado
unpublish
data
ic
rfeifnsuggest
ca
time
effect
inhibit
fiv
rt
collado
unpublish
data
collect
result
treatment
rfeifnof
felvor
fivinfect
cell
demonstr
ifn
appar
inhibit
felin
retroviru
gene
express
suppress
process
assembl
viral
protein
andor
releas
virion
late
stage
matur
summari
profound
antivir
effect
rfeifnov
observ
vitro
felv
fiv
part
may
due
speciesspecif
typei
interferon
homolog
natur
rfeifnand
felin
cell
line
difficult
predict
possibl
clinic
applic
interferon
base
vitro
studi
due
varieti
physiolog
condit
present
vivo
myriad
individu
respons
treat
anim
nevertheless
result
vitro
studi
seem
suggest
although
rfeifnor
may
prophylact
therapeut
clinic
valu
rfeifnwould
like
effect
vivo
addit
typei
ifn
immun
modul
properti
concurr
antivir
activ
measur
vitro
propos
research
gerlach
et
al
thu
enhanc
effect
rfeifnmay
expect
vivo
due
therapeut
possibl
interferon
felin
retrovirosi
sever
studi
undertaken
differ
typei
ifn
protocol
although
result
date
inconclus
initi
experi
inject
felvinfect
cat
singularli
combin
azt
zeidner
et
al
viral
antigen
load
antigenemia
observ
decreas
howev
benefici
respons
limit
durat
cat
develop
antibodi
human
ifn
reduc
develop
antibodi
lower
dose
ifn
administ
oral
iukg
bodi
weight
result
longer
surviv
rate
studi
clinic
analyt
improv
note
steed
cummin
et
al
weiss
et
al
other
although
improv
mccaw
et
al
similarli
oral
treatment
clinic
sick
fivinfect
cat
low
dose
natur
result
extend
surviv
period
improv
clinic
sign
pedretti
et
al
spite
clinic
benefit
treatment
felvand
fivinfect
cat
becam
persist
virem
reduc
viral
replic
treatment
period
mccaw
et
al
pedretti
et
al
addit
low
oral
dose
ineffect
regard
lymphocyt
deplet
relev
variat
ratio
treatment
naturallyinfect
felv
cat
riondato
et
al
low
dose
even
fail
maintain
balanc
cell
fivinfect
cat
riondato
et
al
pedretti
et
al
moreov
alter
ratio
evid
correl
clinic
condit
pedretti
et
al
howev
correl
found
clinic
condit
leukocyt
count
suggest
treat
cat
undergo
strengthen
innat
immun
respons
better
control
opportunist
infect
pedretti
et
al
synthesi
commerci
recombin
felin
ifnmolecul
studi
felin
medicin
focus
applic
present
interferon
european
medicin
agenc
http
emeaeuropaeu
regist
europ
felin
medicin
approv
treatment
parvovirosi
dog
one
month
age
felv
andor
fiv
infect
nontermin
cat
age
week
http
emeaeuropaeu
yet
studi
analyz
effect
rfeifnin
naturallyinfect
cat
felv
andor
fiv
one
extens
studi
undertaken
evalu
interferon
multicentr
doubleblind
placebocontrol
trial
felvinfect
felvfiv
coinfect
cat
associ
clinic
sign
de
mari
et
al
cat
treat
subcutan
rfeifn
ukgday
daili
five
consecut
day
three
seri
day
improv
clinic
sign
decreas
mortal
rate
observ
treatment
compar
control
anim
also
increas
leukogram
rbc
count
anem
cat
de
mari
et
al
howev
virolog
viremia
provir
load
immunolog
ratio
paramet
measur
throughout
studi
difficult
conclud
whether
effect
due
immunomodulatori
antivir
activ
sinc
ifnha
biolog
properti
similar
possibl
clinic
benefit
observ
treat
cat
correspond
activ
innat
immun
system
improv
control
environment
pathogen
compar
improv
virem
state
studi
necessari
order
discov
answer
question
one
control
clinic
trial
perform
asymptomat
fivinfect
cat
use
low
ucatday
oral
six
week
high
ukgday
subcutan
inject
five
day
dose
rfeifn
improv
laboratori
paramet
provir
load
tcell
count
total
white
blood
cell
count
wbc
observ
caney
et
al
knowledg
clinic
studi
perform
effect
interferon
symptomat
fivinfect
cat
veterinari
practition
treat
felvandor
fivinfect
cat
usual
know
cat
infect
stage
diseas
cat
may
one
clinic
sign
may
total
asymptomat
practition
may
know
immun
statu
anim
ratio
provir
load
thu
treatment
rfeifnmay
produc
differ
result
expect
rang
visibl
effect
appar
clinic
improv
big
concern
clinic
veterinarian
whether
improv
correl
true
improv
infect
ie
decreas
viremia
provir
load
cat
whether
infect
may
revert
treatment
rfeifni
suspend
treatment
also
hamper
cost
product
compani
recommend
three
cycl
treatment
five
consecut
day
day
usual
clinic
improv
oftentim
owner
consid
cat
cure
suspend
treatment
complet
anoth
issu
practition
decid
treatment
repeat
analyt
valu
avail
reason
undertook
preliminari
studi
use
rfeifnin
randomli
select
household
cat
brought
complutens
univers
veterinari
clinic
hospit
madrid
spain
eleven
naturallyinfect
cat
treat
four
infect
felv
felv
seven
infect
fiv
fiv
age
rang
month
year
includ
male
femal
mix
breed
differ
regim
roam
treat
eight
week
commerci
rfeifn
virbagen
virbac
franc
follow
protocol
suggest
de
mari
et
al
ten
cat
five
felv
five
fiv
eight
femal
hous
catteri
left
untreat
use
control
date
infect
unknown
case
presum
cat
differ
stage
diseas
sinc
includ
three
asymptomat
fiv
cat
ten
cat
felv
fiv
six
differ
retrovirusassoci
clinic
sign
rac
variou
degre
sever
clinic
score
sever
diseas
frequent
disord
anorexia
apathi
pallor
oral
lesion
blood
sampl
taken
begin
treatment
two
week
complet
equival
sampl
date
untreat
cat
three
treat
cat
brought
followup
examin
month
blood
sampl
hemogram
leukogram
biochem
profil
electrophoretogram
determin
conduct
describ
previous
miro
et
al
felv
fiv
protein
evalu
use
commerci
petchek
kit
develop
idexx
westbrook
usa
rt
activ
measur
kit
provid
cavidi
tech
uppsala
sweden
quantit
pcr
qpcr
conduct
use
procedur
describ
pinch
et
al
leutenegg
et
al
result
statist
analyz
use
statgraph
differ
anova
chisquar
valu
p
consid
signific
anim
handl
treatment
reagent
manipul
data
collect
carri
complianc
guidelin
good
clinic
practic
good
laboratori
practic
anim
welfar
committe
veterinari
clinic
hospit
complutens
univers
madrid
experiment
procedur
approv
institut
anim
care
use
committe
complutens
univers
treatment
rfeifn
subsequ
month
evid
clinic
improv
observ
sick
treat
cat
especi
clinic
score
cs
tabl
improv
observ
untreat
cat
p
asymptomat
cat
mild
diseas
remain
stabl
clinic
improv
agre
data
de
mari
et
al
studi
pedretti
et
al
one
treat
one
untreatedfelv
cat
tabl
chang
clinic
score
cs
analyt
paramet
immedi
treatment
two
week
treatment
nn
nn
nn
nn
nn
nn
u
felv
nn
nn
nn
nn
nn
nn
f
fiv
nn
nn
nn
nn
nn
u
fiv
nn
nn
nn
nn
nn
nn
u
fiv
nn
nn
nn
nn
nn
nn
f
neg
u
fiv
nn
nn
nn
nn
nn
nn
f
nn
nn
neg
neg
u
fiv
nn
nn
nn
nn
nn
cs
rate
describ
previous
collado
et
al
submit
public
erythrogram
leukogram
electrophoretogram
ratio
situat
provid
follow
n
within
normal
limit
normal
limit
normal
limit
viral
paramet
chang
provid
follow
decreas
increas
stabl
f
favor
chang
u
unfavor
chang
pcv
pack
cell
volum
hgb
hemoglobin
concentr
rbc
erythrocyt
count
leuko
leukocyt
count
ntr
neutrophil
count
lymph
lymphocyt
count
electroph
electrophoretogram
gammaglobulin
concentr
nd
determin
neg
detect
limit
kit
sever
initi
diseas
cs
cs
respect
die
treat
cat
initi
present
erythrogram
leukogram
valu
outsid
norm
show
improv
agre
previou
report
ifn
effect
anem
cat
de
mari
et
al
howev
one
treat
fiv
cat
develop
lymphocytosi
anoth
lymphopenia
tabl
three
cat
examin
wors
clinic
hematolog
condit
data
shown
untreat
cat
initi
normal
erythrogram
leukogram
valu
howev
three
nontreat
cat
unfavor
chang
sever
hematolog
paramet
although
valu
neutrophil
count
improv
sporad
two
nontreat
cat
initi
cat
hypergammaglobulinemia
low
ag
ratio
felv
cat
two
fiv
cat
signific
decreas
gammaglobulin
concentr
p
observ
five
treat
cat
fiv
felv
sustain
cat
follow
till
hypergammaglobulinem
shortli
period
data
shown
gammaglobulin
level
untreat
cat
paramet
initi
abnorm
high
alway
remain
normal
limit
rfeifntreat
cat
ratio
decreas
one
felv
cat
two
fiv
cat
improv
ratio
observ
two
anoth
three
ratio
increas
decreas
tabl
riondato
et
al
observ
correl
ratio
variat
clinic
sign
sick
healthi
cat
similar
ratio
agre
result
provir
load
detect
anim
one
treat
fiv
cat
decreas
initi
provir
load
still
within
detect
limit
treat
untreat
cat
becam
neg
one
treatedfelv
one
treatedfiv
cat
provir
load
increas
though
display
worsen
clinic
condit
regard
viremia
felv
cat
posit
rt
capsid
protein
cat
respons
interferon
variabl
tabl
one
treat
felv
cat
worsen
viral
paramet
cs
decreas
caney
et
al
observ
effect
rfeifnon
provir
load
date
vivo
mechan
typei
ifn
retrovir
infect
unknown
murin
model
friend
murin
leukemia
retroviru
immunomodulatori
effect
seem
import
antivir
effect
induct
antivir
enzym
gerlach
et
al
preliminari
studi
rfeifninduc
evid
improv
clinic
condit
treat
cat
well
hemogram
paramet
ratio
improv
inconsist
virolog
paramet
provir
load
viremia
seen
affect
treatment
suggest
rfeifnposs
lack
antivir
effect
vivo
rather
may
immunomodulatori
effect
take
result
consider
would
seem
advis
treat
retrovirusinfect
cat
interferon
clinic
sign
would
benefit
effect
improv
clinic
condit
